Total trials
2,069
Active
225
Phase 3
548
Total enrollment
1,126,830
Pipeline matrix
Showing 40 of 193 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Tirzepatide | — | — | 73 | ||||
| Mirikizumab | — | — | 24 | ||||
| Pirtobrutinib | — | — | — | 16 | |||
| Lebrikizumab | — | — | 17 | ||||
| Antihyperglycemic medication | — | — | — | — | — | 1 | |
| Idelalisib | — | — | — | — | — | 1 | |
| Abemaciclib | — | 53 | |||||
| Orforglipron | — | — | — | — | 31 | ||
| Retatrutide | — | — | 19 | ||||
| Pembrolizumab | — | — | — | 20 | |||
| Eloralintide | — | — | — | 12 | |||
| Cisplatin | — | — | 82 | ||||
| Carboplatin | — | — | 58 | ||||
| Fulvestrant | — | — | 15 | ||||
| Donanemab | — | — | 13 | ||||
| Gemcitabine | — | — | — | 99 | |||
| LY3537031 | — | — | — | 9 | |||
| Anastrozole | — | — | — | 9 | |||
| Brenipatide | — | — | — | 7 | |||
| Baricitinib | — | 51 | |||||
| Letrozole | — | — | — | 8 | |||
| Imlunestrant | — | — | — | 8 | |||
| Exemestane | — | — | — | 6 | |||
| Pemetrexed | — | 109 | |||||
| Tamoxifen | — | — | — | 7 | |||
| Selpercatinib | — | — | 16 | ||||
| Dulaglutide | — | — | 36 | ||||
| Topical Corticosteroid | — | — | — | — | — | 6 | |
| Ramucirumab | — | — | 49 | ||||
| Paclitaxel | — | — | 37 | ||||
| Galcanezumab | — | — | 18 | ||||
| Adalimumab | — | — | — | — | 7 | ||
| Bevacizumab | — | — | — | 14 | |||
| Erlotinib | — | — | — | 11 | |||
| LY3537982 | — | — | — | 8 | |||
| Semaglutide | — | — | — | 7 | |||
| Durvalumab | — | — | — | — | 5 | ||
| LY3650150 | — | — | — | — | — | 2 | |
| Standard therapy for INCS | — | — | — | — | — | 2 | |
| Lepodisiran | — | — | — | — | 2 |
153 more active programs hidden
Next readouts
- 2015-03-20
- 2017-01-31
- 2017-02-14
- 2017-09-15
- 2018-02-16
- 2018-06-15
- 2019-01-23
- 2019-03-29
- 2020-02-03
- 2020-02-27
Top conditions
- Healthy287
- Diabetes Mellitus, Type 2125
- Healthy Volunteers87
- Obesity86
- Overweight65
- Type 2 Diabetes54
- Diabetes Mellitus, Type 145
- Breast Cancer44
Frequently asked questions about Eli Lilly and Company
- How many clinical trials does Eli Lilly and Company have on ClinicalTrials.gov?
- Eli Lilly and Company is listed as the lead sponsor on 2,069 clinical trials in ClinicalTrials.gov, 225 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Eli Lilly and Company's trials are in Phase 3?
- 548 of Eli Lilly and Company's trials are in Phase 3, spread across 193 active drug programs.
- What therapeutic areas does Eli Lilly and Company focus on?
- Eli Lilly and Company's most-studied conditions on ClinicalTrials.gov are Healthy, Diabetes Mellitus, Type 2, Healthy Volunteers, Obesity, Overweight.
- When are Eli Lilly and Company's next clinical trial readouts?
- Eli Lilly and Company has 10 upcoming primary-completion readouts tracked here; the soonest is “A Study of LY2784544 in Participants With Myeloproliferative Neoplasms”, expected around 2015-03-20.